ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Jacksonville, FL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Endometrial Cancer
Non-Small-Cell Lung Carcinoma
Ovarian Cancer

Triple Negative Breast Cancer trials near Jacksonville, FL, USA:

Study of Magrolimab Combination Therapy in Patients With Non-Surgically Removable Locally Advanced or Metastatic Triple-Negative Breast Cancer (ELEVATE TNBC)

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Jacksonville, Florida, United States and 44 other locations

or pembrolizumab plus capecitabine in participants with triple negative breast cancer that still remains after su...

Enrolling
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Sacituzumab govitecan-hziy (SG)

Phase 3

Gilead Sciences
Gilead Sciences

Jacksonville, Florida, United States and 158 other locations

CAR T-cell therapy, in patients with ROR1+ relapsed or refractory triple negative breast cancer (TNBC), non-small...

Enrolling
Relapsed Cancer
TNBC - Triple-Negative Breast Cancer
Biological: LYL797

Phase 1

Lyell Immunopharma

Jacksonville, Florida, United States and 17 other locations

This is a Phase III, randomised, open-label, 3-arm, multicentre, international study assessing the efficacy and safety of Dato-DXd with or without du...

Enrolling
Breast Cancer
Drug: Paclitaxel
Drug: Dato-DXd

Phase 3

AstraZeneca
AstraZeneca

Jacksonville, Florida, United States and 285 other locations

This study will test the safety of a drug called SGN-B7H4V in participants with solid tumors. It will also study the side effects of this dr...

Enrolling
Ovarian Neoplasms
Hormone Receptor Positive Breast Neoplasms
Drug: SGN-B7H4V

Phase 1

Seagen
Seagen

Jacksonville, Florida, United States and 18 other locations

TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase...

Active, not recruiting
Cancer
Drug: cetuximab
Drug: TTX-080

Phase 1

Tizona Therapeutics

Fleming Island, Florida, United States and 39 other locations

The goal of this study is to learn if giving cemiplimab and vidutolimod together could be effective in treating advanced cancer. The main qu...

Active, not recruiting
Triple Negative Breast Cancer
Non-Small Cell Lung Cancer
Drug: cemiplimab
Drug: vidutolimod

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Jacksonville, Florida, United States and 23 other locations

The objective of this study is to assess safety and efficacy of CAB-ROR2-ADC in solid tumors...

Enrolling
Non Small Cell Lung Cancer
Head and Neck Cancer
Biological: PD-1 inhibitor
Biological: CAB-ROR2-ADC

Phase 1, Phase 2

BioAtla

Fleming Island, Florida, United States and 65 other locations

is to evaluate the safety of acasunlimab (also known as GEN1046) as monotherapy and in combination therapies in patients with malignant solid tumors...

Active, not recruiting
Non-small Cell Lung Cancer
Triple Negative Breast Cancer
Biological: Acasunlimab in combination with pembrolizumab (in a separate expansion cohort)
Biological: Acasunlimab in combination with docetaxel (in a single expansion cohort)

Phase 1, Phase 2

Genmab
Genmab

Jacksonville, Florida, United States and 56 other locations

-small-cell lung cancer (NSCLC), triple negative breast cancer (TNBC), ovarian cancer (OC), end...

Active, not recruiting
Castration-resistant Prostate Cancer
Lower Esophageal Cancer
Drug: cabozantinib
Drug: atezolizumab

Phase 1, Phase 2

Exelixis
Exelixis

Jacksonville, Florida, United States and 123 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems